These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1122 related articles for article (PubMed ID: 30292481)

  • 1. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial.
    Jault P; Leclerc T; Jennes S; Pirnay JP; Que YA; Resch G; Rousseau AF; Ravat F; Carsin H; Le Floch R; Schaal JV; Soler C; Fevre C; Arnaud I; Bretaudeau L; Gabard J
    Lancet Infect Dis; 2019 Jan; 19(1):35-45. PubMed ID: 30292481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial.
    Laterre PF; Colin G; Dequin PF; Dugernier T; Boulain T; Azeredo da Silveira S; Lajaunias F; Perez A; François B
    Lancet Infect Dis; 2019 Jun; 19(6):620-630. PubMed ID: 31056427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineered Superinfective Pf Phage Prevents Dissemination of Pseudomonas aeruginosa in a Mouse Burn Model.
    Prokopczuk FI; Im H; Campos-Gomez J; Orihuela CJ; Martínez E
    mBio; 2023 Jun; 14(3):e0047223. PubMed ID: 37039641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial.
    Kim P; Sanchez AM; Penke TJR; Tuson HH; Kime JC; McKee RW; Slone WL; Conley NR; McMillan LJ; Prybol CJ; Garofolo PM
    Lancet Infect Dis; 2024 Dec; 24(12):1319-1332. PubMed ID: 39134085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial.
    Leitner L; Ujmajuridze A; Chanishvili N; Goderdzishvili M; Chkonia I; Rigvava S; Chkhotua A; Changashvili G; McCallin S; Schneider MP; Liechti MD; Mehnert U; Bachmann LM; Sybesma W; Kessler TM
    Lancet Infect Dis; 2021 Mar; 21(3):427-436. PubMed ID: 32949500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial.
    Beigel JH; Aga E; Elie-Turenne MC; Cho J; Tebas P; Clark CL; Metcalf JP; Ozment C; Raviprakash K; Beeler J; Holley HP; Warner S; Chorley C; Lane HC; Hughes MD; Davey RT;
    Lancet Respir Med; 2019 Nov; 7(11):941-950. PubMed ID: 31582360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving the Inhibitory Effect of Phages against
    Aghaee BL; Khan Mirzaei M; Alikhani MY; Mojtahedi A; Maurice CF
    Viruses; 2021 Feb; 13(2):. PubMed ID: 33670028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of a Broad-Range Bacteriophage Cocktail That Reduces Pseudomonas aeruginosa Biofilms and Treats Acute Infections in Two Animal Models.
    Forti F; Roach DR; Cafora M; Pasini ME; Horner DS; Fiscarelli EV; Rossitto M; Cariani L; Briani F; Debarbieux L; Ghisotti D
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
    Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
    Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months.
    Haworth CS; Shteinberg M; Winthrop K; Barker A; Blasi F; Dimakou K; Morgan LC; O'Donnell AE; Ringshausen FC; Sibila O; Thomson RM; Carroll KJ; Pontenani F; Castellani P; Chalmers JD;
    Lancet Respir Med; 2024 Oct; 12(10):787-798. PubMed ID: 39270696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a phase 1b/2, multicenter, randomized, double-blind, placebo-controlled trial.
    Tamma PD; Souli M; Billard M; Campbell J; Conrad D; Ellison DW; Evans B; Evans SR; Greenwood-Quaintance KE; Filippov AA; Geres HS; Hamasaki T; Komarow L; Nikolich MP; Lodise TP; Nayak SU; Norice-Tra C; Patel R; Pride D; Russell J; Van Tyne D; Chambers HF; FowlerJr VG; Schooley RT;
    Trials; 2022 Dec; 23(1):1057. PubMed ID: 36578069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
    Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
    Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy.
    Wright A; Hawkins CH; Anggård EE; Harper DR
    Clin Otolaryngol; 2009 Aug; 34(4):349-57. PubMed ID: 19673983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
    Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
    Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing bacteriophage treatment of resistant
    Ulrich L; Steiner LX; Giez C; Lachnit T
    mSphere; 2024 Jul; 9(7):e0070723. PubMed ID: 38934592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of lytic bacteriophage in the treatment of multidrug-resistant Pseudomonas aeruginosa septicemia in mice.
    Vinodkumar CS; Kalsurmath S; Neelagund YF
    Indian J Pathol Microbiol; 2008; 51(3):360-6. PubMed ID: 18723958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phage Therapy in a Burn Patient Colonized with Extensively Drug-Resistant
    Teney C; Poupelin JC; Briot T; Le Bouar M; Fevre C; Brosset S; Martin O; Valour F; Roussel-Gaillard T; Leboucher G; Ader F; Lukaszewicz AC; Ferry T;
    Viruses; 2024 Jul; 16(7):. PubMed ID: 39066242
    [No Abstract]   [Full Text] [Related]  

  • 18. Assessing antibacterial efficacy of a polyhexanide hydrogel versus alginate-based wound dressing in burns.
    De Decker I; Janssens D; De Mey K; Hoeksema H; Simaey M; De Coninck P; Verbelen J; De Pessemier A; Blondeel P; Monstrey S; Claes KE
    J Wound Care; 2024 May; 33(5):335-347. PubMed ID: 38683776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
    Wunderink RG; Matsunaga Y; Ariyasu M; Clevenbergh P; Echols R; Kaye KS; Kollef M; Menon A; Pogue JM; Shorr AF; Timsit JF; Zeitlinger M; Nagata TD
    Lancet Infect Dis; 2021 Feb; 21(2):213-225. PubMed ID: 33058798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial.
    Zakrzewska JM; Palmer J; Morisset V; Giblin GM; Obermann M; Ettlin DA; Cruccu G; Bendtsen L; Estacion M; Derjean D; Waxman SG; Layton G; Gunn K; Tate S;
    Lancet Neurol; 2017 Apr; 16(4):291-300. PubMed ID: 28216232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.